$NYXH names Liam Kelly CEO from October 1. U.S. Genio launch, management transition, ACCCESS and the separate regulatory path.

6 track album

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

$NYXH stock hub: ACCCESS hits 77.2% AHI and 87.7% ODI responder rates, zero device-related SAEs, EUR 97.8M cash, 101.8M shares, a convertible, a CEO search.

Just a small vtuber who likes working on art and playing random games :3

Twitch is the world

YouTube video by The Ganja Kru - Topic

ニクソア（Nyxoah）株式の概要です。NYXHの最新終値、チャート、ニュース、分析、アナリストによる評価などをご覧いただけます。

Just a small vtuber who likes working on art and playing random games :3

Nyxoah (NYXH) announced that Chief Financial Officer John Landry will step down effective October 2, 2026, and reaffirmed its full-year 2026 financial guidance.Loïc Moreau, currently President International and former CFO, will assume the role of interim CFO upon Landry’s departure while a search for a permanent successor is conducted. The company continues to expect 2026 worldwide net revenue between €36 million and €40 million, gross margin between 60% and 62%, total operating expenses between €99 million and €102 million, and non-GAAP cash operating expenses between €88 million and €90 million.Nyxoah develops the Genio hypoglossal neurostimulation system for obstructive sleep apnea, which has held a CE Mark since 2019 and received FDA approval in August 2025 as a prescription-only device.

INSIDE INFORMATION REGULATED INFORMATION Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea U.S. Commercialization Officially Launched Mont-Saint-Guibert,...

Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate

Nyxoah (NYXH) reported implantation of the first patient in BREATHE, its U.S. post-approval study of the Genio® hypoglossal nerve stimulation system for obstructive sleep apnea.BREATHE is a multicenter, prospective, single-arm study in adults with moderate to severe OSA, planning to implant up to 229 patients at up to 25 U.S. centers with follow-up for up to five years. Co-primary effectiveness endpoints are Apnea-Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI) responder rates at 12 months, while safety endpoints track device- and procedure-related serious adverse events at 12 months and annually thereafter. The company said BREATHE will build long-term, real-world evidence for Genio in routine clinical practice.